Mary Ann Chirba has spoken and written extensively on the legal and regulatory aspects of emerging cellular therapies. She holds a Juris Doctorate from Boston College Law School, a Doctorate of Science and a Master’s in Public Health in Health Policy from the Harvard School of Public Health, and a Bachelor of Arts in Biology from Colgate University. She a Professor at Boston College Law School where her courses have included Comparative Health Law; Legal Reasoning, Research and Writing; Health Care Law and Policy I and II; Appellate Advocacy; Advocacy Writing; and Product Liability Law. At the Harvard School of Public Health, Professor Chirba has taught courses on Pharmaceutical Product Law and Regulation; “The Tobacco Wars;” Current Developments in Health Law; Managed Care Law & Regulation; and Medical Malpractice & Risk Management. Her research interests focus broadly on how law and regulation can promote or impede desired health outcomes with a particular emphasis on domestic and international regulation of adult stem cell therapies, regulation of medical drugs and devices, and federal and comparative health care reform. In addition to her many articles, she recently co-authored the treatise HEALTH CARE REFORM: LAW AND PRACTICE (M. Chirba, A. Noble, O’Melveny & Myers; Lexis/Matthew Bender 2013), which details statutory and regulatory compliance obligations under the Affordable Care Act.